AlphaYou
Overview
Key stats
Fundamentals Sep 10- Open
- $2.74
- 52-wk high
- $3.11
- High
- $2.78
- 52-wk low
- $1.12
- Low
- $2.69
- Prev close
- $2.75
- Mkt cap
- $537.1M
- Volume
- 1.26M
- Fwd P/E
- 1.8x
- Beta
- 0.25
- P/S
- 339.3x
- P/B
- 2.6x
- Profit margin
- +0.0%
- Op margin
- -2101.0%
- ROE
- -26.0%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
Earnings
Earnings came in 20.0% above what analysts expected.
Earnings per share
-$0.08+20.0%
-$0.10 expected
What the street expects next
EPS expected
-$0.09
-$0.10 to -$0.08
Revenue expected
$14.2K
10 analysts
Last 30 days
1up3down
Analysts cutting estimates
Estimate drift
+0.02
Change in 30 days
Financials
What it sold, what it cost, what was left.
Sep 2025Dec 2025Mar 2026Jun 2026
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $132.0K | $718.0K | $0 | $733.0K |
| Cost of what it sold | $17.0K | $44.0K | $35.0K | $16.0K |
| Gross profit | $132.0K | $718.0K | -$35.0K | $733.0K |
| What it spent | ||||
| Research and development | $5.9M | $6.6M | $11.2M | $10.0M |
| Sales and admin | $6.8M | $6.4M | $6.7M | $6.2M |
| Other operating costs | — | — | — | $300.0K |
| Total operating expenses | $12.7M | $13.0M | $17.8M | $16.4M |
| What was left | ||||
| Operating profit | -$12.5M | -$12.3M | -$17.8M | -$15.7M |
| Profit before tax | -$12.2M | $9.7M | -$17.0M | -$15.0M |
| Net profit | -$12.2M | $9.7M | -$17.0M | -$15.0M |
| EBITDA | -$12.1M | $9.7M | -$17.8M | -$15.4M |
Technicals
Price structure
This stock is trending upward.
Trend
Constructive
65 / 100
RSI 14
39balanced
20D volatility
51%annualized
52-week range
$1.12$3.10
20D support
$2.43recent floor
20D resistance
$2.95recent ceiling
Returns
5D -2.2%20D +4.7%60D +17.4%
Price vs moving averages
SMA20 -3.5%SMA50 +3.1%SMA200 +22.2%
Volume pace
1.00xvs prior 20D
News
What the news says
1 article · 7 days
Coverage is bearish
Tone of tracked coverage
Ovid Therapeutics (OVID) insider prepares new stock sale after recent August trades
Leans bearishAug 24